

CLAIMS:

1. A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any of:

(a) SEQ ID Nos: 27 to 45;

5 (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

(c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to
10 the corresponding polypeptide of (a) or (b).

2. A nucleic acid molecule comprising a nucleic acid sequence selected from any of:

(a) SEQ ID Nos: 1 to 26;

(b) a sequence which encodes a polypeptide encoded by
15 any one of SEQ ID Nos: 1 to 26;

(c) a sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (a) and (b); and

(d) a sequence which encodes a polypeptide which is
20 at least 75% identical in amino acid sequence to any one of the polypeptides encoded by SEQ ID Nos: 1 to 26.

3. A nucleic acid molecule comprising a nucleic acid sequence which is anti-sense to the nucleic acid molecule of claim 1.

25 4. A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule according to claim 1 and a second polypeptide.

5. The nucleic acid molecule of claim 4 wherein the second polypeptide is a heterologous signal peptide.

6. The nucleic acid molecule of claim 4 wherein the second polypeptide has adjuvant activity.

5 7. A nucleic acid molecule according to claim 1, operatively linked to one or more expression control sequences.

8. A vaccine comprising a vaccine vector and at least one first nucleic acid selected from any of:

(i) SEQ ID Nos: 1 to 26;

10 (ii) a nucleic acid sequence which encodes a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);

15 (iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(v) a nucleic acid sequence which encodes a
20 polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(vi) a nucleic acid sequence which encodes an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

25 (vii) a nucleic acid sequence which encodes a polypeptide as defined in (v) or an immunogenic fragment as defined in (vi) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the

corresponding polypeptide of (v) or the corresponding fragment of (vi);

wherein each first nucleic acid is capable of being expressed.

- 5 9. A vaccine comprising a vaccine vector and at least one first nucleic acid encoding a fusion protein, wherein the fusion protein comprises:

(a) a first polypeptide selected from any of:

10 (i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

15 (iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

20 (v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or
25 fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v); and

(b) a second polypeptide;

wherein each first nucleic acid is capable of being expressed.

10. The vaccine of claim 9 wherein the second polypeptide is a heterologous signal peptide.

5 11. The vaccine of claim 9 wherein the second polypeptide has adjuvant activity.

12. The vaccine of claim 8 wherein each first nucleic acid is operatively linked to one or more expression control sequences.

10 13. A vaccine according to claim 8 wherein each first nucleic acid is expressed as a polypeptide, and wherein the vaccine comprises a second nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by the first nucleic acid.

15 14. The vaccine of claim 13 wherein the second nucleic acid encodes an additional *Chlamydia* polypeptide.

15. A pharmaceutical composition comprising a nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.

20 16. A pharmaceutical composition comprising a vaccine according to claim 8 and a pharmaceutically acceptable carrier.

17. A unicellular host transformed with the nucleic acid molecule of claim 7.

18. An isolated nucleic acid probe of 5 to 100
25 nucleotides which hybridizes under stringent conditions to any one of nucleic acid molecules of SEQ ID Nos: 1 to 26, or to a complementary or anti-sense sequence of said nucleic acid molecule.

19. A primer of 10 to 40 nucleotides which hybridizes
30 under stringent conditions to any one of nucleic acid molecules

of SEQ ID Nos: 1 to 26, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

20. A polypeptide encoded by a nucleic acid sequence according to claim 2.

5 21. A polypeptide comprising an amino acid sequence selected from any of:

(a) SEQ ID Nos: 27 to 45;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

10 (c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

15 22. A fusion protein comprising a polypeptide of claim 20 and a second polypeptide.

23. The fusion protein of claim 22 wherein the second polypeptide is a heterologous signal peptide.

24. The fusion protein of claim 22 wherein the second polypeptide has adjuvant activity.

20 25. A method for producing a polypeptide of claim 20, comprising the step of culturing a unicellular host of claim 17.

26. An antibody against the polypeptide of claim 20.

25 27. A vaccine comprising at least one first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

5 (iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

10 (v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined in (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified
15 polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v).

28. A vaccine comprising at least one fusion protein, wherein the fusion protein comprises:

20 (a) a first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of
25 SEQ ID Nos: 1 to 26;

(iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any
30 one of SEQ ID Nos: 27 to 45;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v); and

10 (b) a second polypeptide.

29. The vaccine of claim 28 wherein the second polypeptide is a heterologous signal peptide.

30. The vaccine of claim 28 wherein the second polypeptide has adjuvant activity.

15 31. A vaccine comprising at least one first polypeptide according to claim 20 and an additional polypeptide which enhances the immune response to the first polypeptide.

32. The vaccine of claim 31 wherein the additional polypeptide comprises a *Chlamydia* polypeptide.

20 33. A pharmaceutical composition comprising a polypeptide according to claim 20 and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising a vaccine according to claim 27 and a pharmaceutically acceptable
25 carrier.

35. A pharmaceutical composition comprising an antibody according to claim 26 and a pharmaceutically acceptable carrier.

36. A method for preventing or treating *Chlamydia* infection comprising administering to a patient an effective amount of:

(a) a nucleic acid molecule according to claim 2; ✓

5 (b) a vaccine comprising a vaccine vector and at least one first nucleic acid according to claim 2;

(c) a pharmaceutical composition comprising a nucleic acid according to claim 2 and a pharmaceutically acceptable carrier;

10 (d) a polypeptide encoded by a nucleic acid sequence according to claim 2; or

(e) an antibody against a polypeptide encoded by a nucleic acid sequence according to claim 2.

37. A method of detecting *Chlamydia* infection comprising
15 the step of contacting a body fluid of a mammal to be tested, with a component selected from any one of:

(a) a nucleic acid molecule according to claim 2;

(b) a polypeptide encoded by a nucleic acid sequence according to claim 2; and

20 (c) an antibody against a polypeptide encoded by a nucleic acid sequence according to claim 2.

38. A diagnostic kit comprising instructions for use and a component selected from any one of:

(a) a nucleic acid molecule according to claim 2; ✓

25 (b) a polypeptide encoded by a nucleic acid sequence according to claim 2; and

(c) an antibody against a polypeptide encoded by a nucleic acid sequence according to claim 2.

39. A method for identifying a polypeptide of claim 20 which induces an immune response effective to prevent or lessen the severity of *Chlamydia* infection in a mammal previously immunized with polypeptide, comprising the steps of:

5 (a) immunizing a mouse with a polypeptide of claim 20; and

(b) inoculating the immunized mouse with *Chlamydia*;

wherein the polypeptide which prevents or lessens the severity of *Chlamydia* infection in the immunized mouse compared
10 to a non-immunized control mouse is identified.

CLAIMS

1. A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any of:

- 5 (a) SEQ ID Nos: 27 to 45;
- (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and
- (c) a polypeptide of (a) or (b) which has been modified to improve its immunogenicity, wherein said modified
- 10 polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

2. A nucleic acid molecule comprising a nucleic acid sequence selected from any of:

- 15 (a) SEQ ID Nos: 1 to 26;
- (b) a sequence which encodes a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;
- (c) a sequence comprising at least 38 consecutive
- 20 nucleotides from any one of the nucleic acid sequences of (a) and (b); and
- (d) a sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to any one of the polypeptides encoded by SEQ ID Nos: 1 to 26.

3. A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule according to claim 1 and an additional polypeptide.
4. A nucleic acid molecule according to claim 1, operatively linked to one or more expression control sequences.
5. A vaccine comprising at least one first nucleic acid according to any one of claims 1 to 4 and a vaccine vector wherein each first nucleic acid is expressed as a polypeptide, the vaccine optionally comprising a second nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by said first nucleic acid.
6. The vaccine of claim 5 wherein the second nucleic acid encodes an additional *Chlamydia* polypeptide.
7. A pharmaceutical composition comprising a nucleic acid according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising a vaccine according to claim 5 or 6 and a pharmaceutically acceptable carrier.

5 9. A unicellular host transformed with the nucleic acid molecule of claim 4.

10. A nucleic acid probe of 5 to 100 nucleotides which hybridizes under stringent conditions to any one of nucleic acid molecules of SEQ ID Nos: 1 to 26, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

11. A primer of 10 to 40 nucleotides which hybridizes under stringent conditions to any one of nucleic acid molecules of SEQ ID Nos: 1 to 26, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

20 12. A polypeptide encoded by a nucleic acid sequence according to any one of claims 1 to 4.

13. A polypeptide comprising an amino acid sequence selected from any of:

25 (a) SEQ ID Nos: 27 to 45;

- (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and
- (c) a polypeptide of (a) or (b) which has been modified to improve its immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

14. A fusion polypeptide comprising a polypeptide of claim 12 or 13 and an additional polypeptide.

15. A method for producing a polypeptide of claim 12 or 13, comprising the step of culturing a unicellular host according to claim 9.

15

16. An antibody against the polypeptide of any one of claims 12 to 14.

17. A vaccine comprising at least one first polypeptide according to any one of claims 12 to 14 and a pharmaceutically acceptable carrier, optionally comprising a second polypeptide which enhances the immune response to the first polypeptide.

18. The vaccine of claim 17 wherein the second polypeptide comprises an additional *Chlamydia* polypeptide.

19. A pharmaceutical composition comprising a polypeptide according to any one of claims 12 to 14 and a pharmaceutically acceptable carrier.
- 5 20. A pharmaceutical composition comprising a vaccine according to claim 17 or 18 and a pharmaceutically acceptable carrier.
- 10 21. A pharmaceutical composition comprising an antibody according to claim 16 and a pharmaceutically acceptable carrier.
22. A method for preventing or treating *Chlamydia* infection using:
- 15 (a) the nucleic acid of any one of claims 1 to 4;
(b) the vaccine of any one of claims 5, 6, 17 and 18;
(c) the pharmaceutical composition of any one of claims 7, 8, 19 to 21;
20 (d) the polypeptide of any one of claims 12 to 14; or
(e) the antibody of claim 16.
23. A method of detecting *Chlamydia* infection comprising the step of assaying a body fluid of a mammal to be tested, with a component selected from any one of:
- 25 (a) the nucleic acid of any one of claims 1 to 4;

- (b) the polypeptide of any one of claims 12 to 14; and
- (c) the antibody of claim 16.

24. A diagnostic kit comprising instructions for use and a
5 component selected from any one of:

- (a) the nucleic acid of any one of claims 1 to 4; ✓
- (b) the polypeptide of any one of claims 12 to 14; and
the antibody of claim 16.